Article Text


Inflammatory bowel disease II
PTU-122 A trial with mercaptopurine following azathioprine intolerance is a safe treatment strategy for the majority of patients with IBD
  1. E B Rhatigan,
  2. N A Kennedy,
  3. I D Arnott,
  4. C L Noble,
  5. A G Shand,
  6. J Satsangi,
  7. C W Lees
  1. Gastrointestinal Unit, Molecular Medicine Centre, Western General Hospital, Edinburgh, UK


Introduction Azathioprine intolerance (AZA-I) leads to withdrawal of therapy in up to 30% of patients with IBD. Smaller case series demonstrated that mercaptopurine (MP) could be a well tolerated alternative in selected patients.1 This study aims to further assess its tolerability, in a larger cohort of AZA-I patients, over a longer period of time, and to re-evaluate potential factors predictive of tolerance.

Methods A retrospective audit was made of 137 patients with IBD (78 women, median age at diagnosis 32 years, 78 with CD, 59 with UC) who had been intolerant of AZA and then subsequently treated with MP.

Results MP was tolerated by 58% of AZA-I patients (median follow-up 937 days, median dose 0.91 mg/kg). Tolerance was highest in patients with AZA related gastrointestinal intolerance (66%) and hepatotoxicity (61%), and lowest in patients with AZA related flu-like illness (40%). The number of patients with AZA induced neutropenia and pancreatitis were too small to draw firm conclusions (see Abstract PTU-122 table 1). Age at diagnosis was significantly associated with tolerability. Patients intolerant of MP were younger (28 vs 33 yro; p=0.024) and of those under the age of 40 only 55% tolerated MP compared with 69% of those aged 40 years or over (p=Azathioprine-intolerant patients, subsequently treated with mercaptopurine (AZA-I/MP) grouped by azathioprine intolerance

Abstract PTU-122 Table 1

Conclusion Consistent with previous data, this, the largest series to date, with substantial follow- up, has shown that MP is a safe alternative for up to 60% of AZA-I patients, including some with a previous major intolerance. Patients with previous gastrointestinal intolerance or hepatotoxicity may be more likely to tolerate a trial of MP.

Competing interests None declared.

Reference 1. Lees, et al. Aliment Pharmacol & Ther 2007;27:220–7.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.